title: Low-dose fenfluramine in the treatment of neurologic disorders: experience in Dravet syndrome.
abstract: In this paper, we review the experience with fenfluramine in epileptic and other paroxysmal disorders. Since the best available data are from the treatment of Dravet syndrome, we will focus primarily on this condition. Originally fenfluramine was launched as an anorectic agent. As early as 1985, seizure reduction in children could be demonstrated in a few cases with photosensitive, self-induced epilepsy. Hereafter, a small study was launched in patients with self-induced epilepsy. Results showed a significant seizure reduction, and review of the patient data showed that 5 of the 12 patients had Dravet syndrome. During that observation period, fenfluramine was withdrawn from the market because of cardiovascular side effects associated with prescribing higher doses in combination with phentermine for weight loss. In March 2002, a Belgian Royal Decree was issued permitting further study of fenfluramine in pediatric patients with intractable epilepsy. In 2011 under the Royal Decree, a prospective study of patients with Dravet syndrome treated with low-dose fenfluramine was initiated and is currently ongoing. The initial results are promising in terms of reduction of seizure frequency and overall tolerability.
authors.affiliation: Department of Neurology-Pediatric Neurology, Antwerp University Hospital, University of Antwerp, Belgium.
authors.forename: An-Sofie
authors.initials: AS
authors.lastname: Schoonjans
authors.affiliation: Department of Pediatric Neurology, University Hospitals Gasthuisberg, Leuven, Belgium.
authors.forename: Lieven
authors.initials: L
authors.lastname: Lagae
authors.affiliation: Department of Neurology-Pediatric Neurology, Antwerp University Hospital, University of Antwerp, Wilrijkstraat 10, 2650 Edegem, Belgium.
authors.forename: Berten
authors.initials: B
authors.lastname: Ceulemans
keywords: Dravet; SCN1A; childhood epilepsy; drug resistance; fenfluramine; serotonin